Virological and drugresistance outcomes for people living with HIV initiating or switching to tenofovir lamivudine and dolutegravir in six PEPFARsupported countries a prospective cohort study

Simple item page
dc.article.end-page849en
dc.article.start-page836en
dc.citation.doi10.1016/S2352-3018(25)00162-6.en
dc.contributor.authorJean Bernard Marcen
dc.contributor.authorC McCarthyen
dc.contributor.authorCarole L Wallisen
dc.contributor.authorCissy Kityoen
dc.contributor.authorLerato Mohapien
dc.contributor.authorMohammed Rassoolen
dc.contributor.authorVuyokazi Jezileen
dc.contributor.authorNoluthando Mwelaseen
dc.contributor.authorE et alen
dc.date.accessioned2026-03-23T10:07:59Z
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2352-3018en
dc.identifier.urihttps://hdl.handle.net/10539/48665
dc.journal.titleVirological and drugresistance outcomes for people living with HIV initiating or switching to tenofovir lamivudine and dolutegravir in six PEPFARsupported countries a prospective cohort studyen
dc.journal.volume12en
dc.titleVirological and drugresistance outcomes for people living with HIV initiating or switching to tenofovir lamivudine and dolutegravir in six PEPFARsupported countries a prospective cohort studyen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
924.56 KB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)